<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255589</url>
  </required_header>
  <id_info>
    <org_study_id>A74_02AG/CG1904</org_study_id>
    <nct_id>NCT04255589</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495</brief_title>
  <official_title>A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Efficacy and Safety of CKD-495
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the
      Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate of gastric erosion</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>50% decreased on erosive grade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cure rate of gastric erosion</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>0 erosion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of symptoms</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>50% decreased on the Subjective Symptoms total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of gastric edema</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>50% decreased on the Edema grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of gastric erythema</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>50% decreased on the Erythema grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of gastric hemorrhage</measure>
    <time_frame>14days after drug administrations</time_frame>
    <description>50% decreased on the Hemorrhage grade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-495 75mg</intervention_name>
    <description>CKD-495 75mg Tab.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg</intervention_name>
    <description>Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.</description>
    <arm_group_label>Active comparator Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of the CKD-495 75mg</intervention_name>
    <description>Placebo of the CKD-495 75mg Tab.</description>
    <arm_group_label>Active comparator Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg</intervention_name>
    <description>Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subjects aged ≥ 19

          2. Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within
             7days prior to the use of the Investigator's Product taken date

          3. Patients who have more than 1 subjective symptom

        Exclusion Criteria:

          1. Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the
             digestive system or coagulation disorder, or taking antithrombotic medicine

          2. Patients who have been taken any gastritis medicine that could affect the treatment:
             H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement
             in digestive system, Prostaglandin, and protective agent for gastritis

          3. Patients who have to take medicine that could cause gastritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oh Young Lee, MD, Ph.D.</last_name>
    <phone>82+2-2290-8343</phone>
    <email>leeoy@hanyang.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Donggu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jong Sun Rew, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Kook Kim, M.D, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Busan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GeunAm Song, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Ryong Jee, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TaeNyeong Kim, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Taek Lee, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DongHo Lee, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Gyu Kim, M.D,Ph D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Young Lee, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hun Jae Jeon, M.D, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jong Jae Park, M.D, Ph D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JaeJune Kim, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Gyun Kim, M.D, Ph D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Chan Lee, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeouido ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Il Kim, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Gastritis</keyword>
  <keyword>Chronic Gastritis</keyword>
  <keyword>Cinnamic acid</keyword>
  <keyword>CKD-495</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

